Opioid Use Disorder Market Is Set To Hit $4.5 Billion By 2026 With A Note Worthy CAGR Of 10.1% | Grand View Research Inc.

Opioid Use Disorder Market Is Set To Hit $4.5 Billion By 2026 With A Note Worthy CAGR Of 10.1% | Grand View Research Inc.

“Grand View Research, Inc. – Market Research And Consulting.”
According to a report published by Grand View Research, the opioid use disorder global market is driven by the factors such as the commercialization of few medications that are licensed for therapy and distributed to different regions.

The global opioid use disorder market size is expected to reach USD 4.5 billion by 2026, exhibiting a CAGR of 10.1% over the forecast period. The rising opioid epidemic and growing government initiatives to combat the crisis are likely to propel market growth. In addition, the growing commercialization of novel products is further anticipated to drive growth. In 2018, about 2.9 million people aged 15 or above were suffering from this disorder in the U.S. In 2016, according to the National Survey on Drug Use and Health (NSDUH), in the U.S., around 11.5 million people had abused prescription opioids in the earlier year and more than 2 million were addicted to prescribed drugs.

According to the CDC, around 130 Americans die every day due to opioid overdose and the U.S. government has designated this as a public health emergency. For patients wanting to overcome their addiction, adherence to a Medication-assisted Treatment (MAT) can reduce the withdrawal symptoms and cut the risk of death by half. Three U.S. FDA-approved MAT options are buprenorphine, methadone, and naltrexone. They are available in numerous dosages and formulations, with daily oral buprenorphine as the standard of care.

To combat the opioid crisis, several measures have been undertaken in recent years. For instance, in 2016, CDC clinical practice guidelines for prescribing these drugs for chronic pain were issued and the new American Society of Addiction Medicine (ASAM) National Practice Guidelines was adopted in 2015 to improve the standard of care. Furthermore, in 2016, the U.S. FDA announced plans to overhaul its regulations for abuse-deterrent opioids, enhance safety labeling, and re-examine the risk-benefit paradigm of their use.

U.S. opioid use disorder market size, by drug, 2015 - 2026 (USD Million)

Opioid Use Disorder Market Report Highlights

  1. On the basis of the drug, Buprenorphine was the largest revenue-generating segment in 2018. Its sublingual tablets and branded drug Suboxone are the most widely prescribed drug for OUD.

  2. Suboxone is the most used medication in the OUD industry. Factors that can be linked to the high use of this drug are high effectiveness in the treatment of addiction, with limited risk for misuse & relatively minor adverse effects, and its beneficial formal coverage.

  3. North America dominated the market in 2018 and is anticipated to maintain its dominance over the forecast period.

  4. In February 2020, the Irish biopharmaceutical firm Alkermes announced that the US Food and Drug Administration (FDA) had cleared its VIVITROL. When the detoxification process is complete, the drug has been engineered to avoid relapse to opioid dependency.

“Would you Like/Try a Sample Report” Click the link below:https://www.grandviewresearch.com/industry-analysis/opioid-use-disorder-market/request/rs1

Opioid Use Disorder Market Segmentation

Grand View Research has segmented the opioid use disorder market on the basis of drug and region:

Opioid Use Disorder Drug Outlook (Revenue, USD Million, 2015 – 2026)

  1. Buprenorphine

    1. Bunavail

    2. Sublocade

    3. Suboxone

    4. Zubsolv

    5. Others

  2. Methadone

  3. Naltrexone

Opioid Use Disorder Regional Outlook (Revenue, USD Million, 2015 – 2026)

  1. North America

    1. The U.S.

    2. Canada

  2. Europe

    1. The U.K.

    2. Germany

    3. France

    4. Italy

    5. Spain

  3. Asia Pacific

    1. Australia

    2. China

  4. Latin America and Middle East & Africa

    1. Brazil

    2. South Africa

Key Players in the Opioid Use Disorder Market

  1. Indivior PLC

  2. BioDelivery Sciences International, Inc.

  3. Alkermes, Inc.

  4. Orexo US, Inc.

  5. Titan Pharmaceuticals, Inc.

  6. Omeros Corporation

  7. Camurus

  8. Hikma Pharmaceuticals PLC

Have Any Query? Ask Our Experts for More Details on Report:https://www.grandviewresearch.com/inquiry/6201/ibb

Browse Related Report @

Opioids Market – https://www.grandviewresearch.com/industry-analysis/opioids-market

Explore the BI enabled intuitive market research database, Navigate with Grand View Compass, by Grand View Research, Inc.

About Grand View Research

Grand View Research is a market research and consulting company that offers market research reports, syndicated and customized reports. The company is headquartered in San Francisco, California. It offers client engagement for business consulting and market intelligence from various domains. The clientele is based across various countries with queries coming from more than 50 industries worldwide.
Grand View Research helps its clients to make informed decisions by helping them understand current trends and scenarios. Every year Grand View Research accomplishes more than 300 multi-country market studies to optimize consulting for clients.

Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1888202951
Address:Grand View Research, Inc. 201 Spear Street 1100 San Francisco, CA 94105, United States
City: San Francisco
State: California
Country: United States
Website: https://www.grandviewresearch.com/industry-analysis/opioid-use-disorder-market